Literature DB >> 20837966

Widening gap in age at muscular dystrophy-associated death between blacks and whites, 1986-2005.

Aileen Kenneson1, Ajay Vatave, Richard Finkel.   

Abstract

BACKGROUND: Muscular dystrophies (MDs), characterized by progressive muscle wasting, are associated with 1 in 2,500 deaths in the United States. Although treatments slow the progression, these disorders lead to early death, usually due to cardiac or respiratory failure.
METHODS: We analyzed death record data from 18,315 MD-associated deaths that occurred in the United States in 1986 through 2005 to assess trends in the age at death of people with MDs.
RESULTS: From 1986 through 2005, the MD-associated mortality rate did not change among blacks, whites, males, or females. The median age at death among white females with MDs was 12 years higher than among black females. The frequency of reported cardiomyopathy increased among white but not black male decedents with MDs, although cardiomyopathy remained more commonly reported among black males. Among white males, the median age at death increased by 0.2 annually for those with and 1.3 for those without indications of cardiomyopathy. Among black males, the median age at death increased 0.3 years annually among those without reported cardiomyopathy. Among white males, the frequencies of pulmonary failure and pulmonary infection decreased significantly over time.
CONCLUSIONS: Changes in age at death and reported clinical comorbidities reflect improvements in the treatment of MDs. White males with MDs have shown a greater increase in age at death over time than black males. Contributing factors to this difference might include differences in types of MDs, rates of genetic and environmental modifiers, natural history, socioeconomic factors, and access to and use of treatment options.

Entities:  

Mesh:

Year:  2010        PMID: 20837966      PMCID: PMC3463014          DOI: 10.1212/WNL.0b013e3181f25e5b

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

Authors:  Michelle Eagle; Simon V Baudouin; Colin Chandler; David R Giddings; Robert Bullock; Kate Bushby
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy.

Authors:  Candice K Silversides; Gary D Webb; Vivien A Harris; Douglas W Biggar
Journal:  Am J Cardiol       Date:  2003-03-15       Impact factor: 2.778

3.  A new lease on life for patients with Duchenne muscular dystrophy in Japan.

Authors:  Fumihiko Yasuma; Masaaki Konagaya; Motoko Sakai; Satoshi Kuru; Takashi Kawamura
Journal:  Am J Med       Date:  2004-09-01       Impact factor: 4.965

4.  Long-term ventilation for patients with Duchenne muscular dystrophy : physicians' beliefs and practices.

Authors:  B Gibson
Journal:  Chest       Date:  2001-03       Impact factor: 9.410

5.  Quality of death rates by race and Hispanic origin: a summary of current research, 1999.

Authors:  H M Rosenberg; J D Maurer; P D Sorlie; N J Johnson; M F MacDorman; D L Hoyert; J F Spitler; C Scott
Journal:  Vital Health Stat 2       Date:  1999-09

6.  Pulmonary care of Duchenne type of muscular dystrophy.

Authors:  G Aberion; A Alba; M H Lee; M Solomon
Journal:  N Y State J Med       Date:  1973-05-15

Review 7.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

8.  Mechanical ventilation of patients with late stage Duchenne muscular dystrophy: management in the home.

Authors:  M A Alexander; E W Johnson; J Petty; D Stauch
Journal:  Arch Phys Med Rehabil       Date:  1979-07       Impact factor: 3.966

9.  Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutations.

Authors:  Tommaso Sanna; Antonio Dello Russo; Daniela Toniolo; Michal Vytopil; Gemma Pelargonio; Giuseppe De Martino; Enzo Ricci; Gabriella Silvestri; Vincenzo Giglio; Loredana Messano; Elisabetta Zachara; Fulvio Bellocci
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

Review 10.  Cardiac involvement in Becker muscular dystrophy.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Can J Cardiol       Date:  2008-10       Impact factor: 5.223

View more
  9 in total

1.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

2.  Summary of Selected Healthcare Encounters among a Selection of Patients with Myotonic Muscular Dystrophy.

Authors:  Kevin J Bennett; Joshua R Mann; Lijing Ouyang
Journal:  South Med J       Date:  2019-06       Impact factor: 0.954

3.  Correlation of heart rate and cardiac dysfunction in Duchenne muscular dystrophy.

Authors:  Tamara O Thomas; Thomas M Morgan; William B Burnette; Larry W Markham
Journal:  Pediatr Cardiol       Date:  2012-03-21       Impact factor: 1.655

Review 4.  Comparative effectiveness and implementation research: directions for neurology.

Authors:  Barbara G Vickrey; Deborah Hirtz; Salina Waddy; Eric M Cheng; S Claiborne Johnston
Journal:  Ann Neurol       Date:  2012-06       Impact factor: 10.422

5.  Selected clinical and demographic factors and all-cause mortality among individuals with Duchenne muscular dystrophy in the Muscular Dystrophy Surveillance, Tracking, and Research Network.

Authors:  Pangaja Paramsothy; Yinding Wang; Bo Cai; Kristin M Conway; Nicholas E Johnson; Shree Pandya; Emma Ciafaloni; Katherine D Mathews; Paul A Romitti; James F Howard; Catharine Riley
Journal:  Neuromuscul Disord       Date:  2022-04-30       Impact factor: 3.538

Review 6.  Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?

Authors:  Michele A Scully; Valerie A Cwik; Bruce C Marshall; Emma Ciafaloni; Jodi M Wolff; Thomas S Getchius; Robert C Griggs
Journal:  Neurology       Date:  2013-02-05       Impact factor: 9.910

7.  Disparities in health care utilization by race among teenagers and young adults with muscular dystrophy.

Authors:  Orgul D Ozturk; Suzanne McDermott; Joshua R Mann; James W Hardin; Julie A Royer; Lijing Ouyang
Journal:  Med Care       Date:  2014-10       Impact factor: 2.983

8.  Characterizing Enrollment in Observational Studies of Duchenne Muscular Dystrophy by Race and Ethnicity.

Authors:  Alison M Barnard; Samuel L Riehl; Rebecca J Willcocks; Glenn A Walter; Amber M Angell; Krista Vandenborne
Journal:  J Neuromuscul Dis       Date:  2020

9.  A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain.

Authors:  Laura Llamosas-Falcón; Germán Sánchez-Díaz; Elisa Gallego; Ana Villaverde-Hueso; Greta Arias-Merino; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.